查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356823

癌症检测筛检市场报告：2030 年趋势、预测与竞争分析

Cancer Testing Screening Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

癌症检测及筛检趋势及预测

预计到 2030 年，全球癌症检测筛检市场将达到 2,142 亿美元，2024 年至 2030 年年复合成长率为 5.1%。该市场的主要驱动因素是癌症患者的盛行率上升、对准确诊断工具和早期检测方法的需求不断增长以及对液体活检的日益偏好。全球癌症检测筛检市场的未来前景广阔，在医院、诊所、诊断中心和研究机构都有应用机会。

癌症测试筛检市场洞察

Lucintel 预测，由于其对癌症的诊断准确性较高，切片检查预计将在预测期内实现最高增长。

医院预计在预测期内将出现最高的成长，因为由于现有基础设施的便利性和医疗专业人员的存在，患者越来越喜欢这些设施进行治疗。

随着前列腺癌和肺癌患者数量持续增加，预计北美地区在预测期内将出现最高增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球癌症检测筛检市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球癌症检测和筛检市场趋势（2018-2023）和预测（2024-2030）
  • 按技术分類的全球癌症检测筛检市场
    • 成像
    • 切片检查
    • 基因组和分子测试
    • 下一代定序
    • RT-PCR
    • 微阵列
    • 生物标记测试
    • 其他的
  • 按癌症类型分類的全球癌症检测筛检市场
    • 呼吸系统癌症
    • 白血病
    • 骨髓瘤和淋巴瘤
    • 皮肤癌
    • 腹部/消化器官系统癌症
    • 泌尿器官系统癌症
    • 内分泌癌
    • 乳癌
    • 其他的
  • 全球癌症检测筛检市场（按应用）
    • 医院
    • 诊所
    • 诊断中心
    • 调查机构
    • 其他的
  • 按最终用途分類的全球癌症检测筛检市场
    • 病人
    • 医疗服务提供方
    • 诊断实验室
    • 调查机构
    • 製药公司

第4章2018-2030年分地区市场趋势及预测分析

  • 全球癌症检测筛检市场（按地区）
  • 北美癌症检测筛检市场
  • 欧洲癌症检测筛检市场
  • 亚太地区癌症检测筛检市场
  • 其他区域癌症检测和筛检市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球癌症检测筛检市场的技术成长机会
    • 按癌症类型分類的全球癌症检测筛检市场成长机会
    • 全球癌症检测筛检市场成长机会（按应用）
    • 全球癌症检测筛检市场成长机会（依最终用途）
    • 全球癌症检测筛检市场成长机会（按地区）
  • 全球癌症检测筛检市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球癌症检测和筛检市场的能力
    • 全球癌症检测筛检市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • DiaSorin
  • Immunodiagnostic Systems
  • Epigenomics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • VolitionRX
  • Abbott Laboratories
  • QIAGEN
  • Siemens Healthineers
简介目录

Cancer Testing Screening Trends and Forecast

The future of the global cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications. The global cancer testing screening market is expected to reach an estimated $214.2 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.

A more than 150-page report is developed to help in your business decisions.

Cancer Testing Screening by Segment

The study includes a forecast for the global cancer testing screening by technique, cancer type, application, end use, and region.

Cancer Testing Screening Market by Technique [Shipment Analysis by Value from 2018 to 2030]:

  • Imaging
  • Biopsy
  • Genomic and Molecular Tests
  • Next Generation Sequencing
  • RT-PCR
  • Microarrays
  • Biomarker Testing
  • Others

Cancer Testing Screening Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Respiratory System Cancer
  • Leukemia
  • Myeloma and Lymphoma
  • Skin Cancer
  • Abdominal/Digestive System Cancer
  • Urinary System Cancer
  • Endocrine System Cancer
  • Breast Cancer
  • Others

Cancer Testing Screening Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Research Institutes
  • Others

Cancer Testing Screening Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Patients
  • Healthcare Providers
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical Companies

Cancer Testing Screening Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Testing Screening Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer testing screening companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer testing screening companies profiled in this report include-

  • Diasorin
  • Immunodiagnostic Systems
  • Epigenomics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • VolitionRX
  • Abbott Laboratories
  • QIAGEN
  • Siemens Healthineers

Cancer Testing Screening Market Insights

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its great accuracy in the diagnosis of cancer.

Hospital is expected to witness highest growth over the forecast perioddue to rising patients preference for this facility for their treatment given to the availibility of well established infrastructure and presence of medical expertise.

North America is expected to witness highest growth over the forecast period due to constant increase in instances of prostate and lung cancer cases in the region.

Features of the Global Cancer Testing Screening Market

Market Size Estimates: Cancer testing screening market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer testing screening market by various segments, such as by technique, cancer type, application, end use and region in terms of($B).

Regional Analysis: Cancer testing screening market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, applications, end uses, and region.s for the cancer testing screening market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer testing screening market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the cancer testing screening market size?

Answer: The global cancer testing screening market is expected to reach an estimated $214.2 billion by 2030.

Q.2. What is the growth forecast for cancer testing screening market?

Answer: The global cancer testing screening market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the cancer testing screening market?

Answer: The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.

Q.4. What are the major segments for cancer testing screening market?

Answer: The future of the cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications.

Q.5. Who are the key cancer testing screening market companies?

Answer: Some of the key cancer testing screening companies are as follows:

  • DiaSorin
  • Immunodiagnostic Systems
  • Epigenomics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • VolitionRX
  • Abbott Laboratories
  • QIAGEN
  • Siemens Healthineers

Q.6. Which cancer testing screening market segment will be the largest in future?

Answer: Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its great accuracy in the diagnosis of cancer.

Q.7. In cancer testing screening market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to constant increase in instances of prostate and lung cancer cases in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer testing screening market by technique (imaging, biopsy, genomic and molecular tests, next generation sequencing, RT-PCR, microarrays, biomarker testing, and others), cancer type (respiratory system cancer, leukemia, myeloma and lymphoma, skin cancer, abdominal/digestive system cancer, urinary system cancer, endocrine system cancer, breast cancer, and others), application (hospitals, clinics, diagnostic centers, research institutes, and others), end use (patients, healthcare providers, diagnostic laboratories, research institutes, and pharmaceutical companies), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Testing Screening Market: Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Testing Screening Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Testing Screening Market by Technique
    • 3.3.1: Imaging
    • 3.3.2: Biopsy
    • 3.3.3: Genomic and Molecular Tests
    • 3.3.4: Next Generation Sequencing
    • 3.3.5: RT-PCR
    • 3.3.6: Microarrays
    • 3.3.7: Biomarker Testing
    • 3.3.8: Others
  • 3.4: Global Cancer Testing Screening Market by Cancer Type
    • 3.4.1: Respiratory System Cancer
    • 3.4.2: Leukemia
    • 3.4.3: Myeloma and Lymphoma
    • 3.4.4: Skin Cancer
    • 3.4.5: Abdominal/Digestive System Cancer
    • 3.4.6: Urinary System Cancer
    • 3.4.7: Endocrine System Cancer
    • 3.4.8: Breast Cancer
    • 3.4.9: Others
  • 3.5: Global Cancer Testing Screening Market by Application
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Diagnostic Centers
    • 3.5.4: Research Institutes
    • 3.5.5: Others
  • 3.6: Global Cancer Testing Screening Market by End Use
    • 3.6.1: Patients
    • 3.6.2: Healthcare Providers
    • 3.6.3: Diagnostic Laboratories
    • 3.6.4: Research Institutes
    • 3.6.5: Pharmaceutical Companies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Testing Screening Market by Region
  • 4.2: North American Cancer Testing Screening Market
    • 4.2.2: North American Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others
  • 4.3: European Cancer Testing Screening Market
    • 4.3.1: European Cancer Testing Screening Market by Technique: Imaging, Biopsy, Genomic and Molecular Tests, Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others
    • 4.3.2: European Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others
  • 4.4: APAC Cancer Testing Screening Market
    • 4.4.1: APAC Cancer Testing Screening Market by Technique: Imaging, Biopsy, Genomic and Molecular Tests, Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others
    • 4.4.2: APAC Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others
  • 4.5: ROW Cancer Testing Screening Market
    • 4.5.1: ROW Cancer Testing Screening Market by Technique: Imaging, Biopsy, Genomic and Molecular Tests, Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others
    • 4.5.2: ROW Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Testing Screening Market by Technique
    • 6.1.2: Growth Opportunities for the Global Cancer Testing Screening Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Cancer Testing Screening Market by Application
    • 6.1.4: Growth Opportunities for the Global Cancer Testing Screening Market by End Use
    • 6.1.5: Growth Opportunities for the Global Cancer Testing Screening Market by Region
  • 6.2: Emerging Trends in the Global Cancer Testing Screening Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Testing Screening Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Testing Screening Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: DiaSorin
  • 7.2: Immunodiagnostic Systems
  • 7.3: Epigenomics
  • 7.4: Quest Diagnostics
  • 7.5: F. Hoffmann-La Roche
  • 7.6: VolitionRX
  • 7.7: Abbott Laboratories
  • 7.8: QIAGEN
  • 7.9: Siemens Healthineers